Discipline of Microbiology, School of Life Sciences, College of Agriculture, Engineering and Science, University of KwaZulu-Natal, Westville Campus, Private Bag X54001, Durban 4000, South Africa.
Molecules. 2017 Jul 26;22(8):1255. doi: 10.3390/molecules22081255.
Several lactic acid bacteria (LAB) isolates from the Lactobacillus genera have been applied in food preservation, partly due to their antimicrobial properties. Their application in the control of human pathogens holds promise provided appropriate strains are scientifically chosen and a suitable mode of delivery is utilized. Urinary tract infection (UTI) is a global problem, affecting mainly diabetic patients and women. Many uropathogens are developing resistance to commonly used antibiotics. There is a need for more research on the ability of LAB to inhibit uropathogens, with a view to apply them in clinical settings, while adhering to strict selection guidelines in the choice of candidate LAB. While several studies have indicated the ability of LAB to elicit inhibitory activities against uropathogens in vitro, more in vivo and clinical trials are essential to validate the efficacy of LAB in the treatment and prevention of UTI. The emerging applications of LAB such as in adjuvant therapy, oral vaccine development, and as purveyors of bioprotective agents, are relevant in infection prevention and amelioration. Therefore, this review explores the potential of LAB isolates and their bacteriocins to control uropathogens, with a view to limit clinical use of antibiotics.
几种乳杆菌属的乳酸菌（LAB）分离株已被应用于食品保鲜，部分原因是它们具有抗菌特性。如果选择合适的菌株并利用适当的传递方式，它们在控制人类病原体方面具有很大的应用前景。尿路感染（UTI）是一个全球性的问题，主要影响糖尿病患者和女性。许多尿路病原体对常用抗生素产生了耐药性。因此，需要进一步研究 LAB 抑制尿路病原体的能力，以期将其应用于临床环境中，同时在选择候选 LAB 时严格遵循选择指南。虽然有几项研究表明 LAB 具有在体外抑制尿路病原体的能力，但仍需要更多的体内和临床试验来验证 LAB 在治疗和预防 UTI 方面的疗效。LAB 的新应用，如辅助治疗、口服疫苗开发和作为生物保护剂的提供者，在感染预防和改善方面具有相关性。因此，本综述探讨了 LAB 分离株及其细菌素控制尿路病原体的潜力，以期限制抗生素的临床使用。
